<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114266">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615653</url>
  </required_header>
  <id_info>
    <org_study_id>09-005037</org_study_id>
    <nct_id>NCT01615653</nct_id>
  </id_info>
  <brief_title>EUS Guided Celiac Neurolysis</brief_title>
  <official_title>Prospective Randomized Trial of EUS Guided Celiac Ganglia Neurolysis (CGN) Versus EUS Guided Celiac Plexus Neurolysis (CPN) for Pancreatic Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Hypothesis:

           - Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the
           efficacy of neurolysis and subsequent pain control and survival in patients with
           pancreatic carcinoma.

        -  Rationale:

             -  Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal
                thereby only briefly remaining in contact with neural structures and limiting the
                degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result
                in diminished neurolysis and decrease efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessed using a numerical rating scale (NRS) from 0 to 10.</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>pain response will be measured</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreatic Cancer Pain</condition>
  <arm_group>
    <arm_group_label>EUS 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS</intervention_name>
    <description>EUS Guided Therapy</description>
    <arm_group_label>EUS 1</arm_group_label>
    <arm_group_label>EUS 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Unresectable pancreatic carcinoma (T4 or M1) or advanced T3 disease

          -  2. Cytologic or histologic confirmation of pancreatic carcinoma

          -  3. Abdominal pain (≥ 3 on NRS scale), ≥ 2 days/week, lasting ≥ 1 hour/ day, stable
             intensity for ≥ 7 days

          -  4. EUS clinically indicated (for non-study purposes)

        Exclusion Criteria:

          -  1. Uncorrectable coagulopathy: (INR) &gt; 1.5 and/or platelets &lt; 50,000

          -  2. Abdominal surgery within 1 month

          -  3. Prior celiac plexus or ganglia neurolysis.

          -  4. Initiation or modification in chemotherapy or radiotherapy within prior 7 days.

          -  5. Direct tumor infiltration of the celiac trunk and/or celiac ganglia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 18, 2015</lastchanged_date>
  <firstreceived_date>April 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael Levy</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Pancreas cancer</keyword>
  <keyword>Pain</keyword>
  <keyword>Celiac Plexus</keyword>
  <keyword>Neurolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
